The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases (PRECEDE)

AstraZeneca

Status: Enrolling

Conditions: Cardiovascular Diseases

Treatments: Behavioral: Guideline education and implementation intervention

Study type: Interventional

Funder types: Industry

Identifiers

NCT06909773

D2287L00041

Details and patient eligibility

About

This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) subjects , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).

Full description

The mainly purpose of this study is describe the prevalence of COPD of the subjects with 3 types of CVD who are aged 40 years or older, and also observe the effect of cardiopulmonary co management on the short term prognosis of subjects with CVD and COPD.

This study will enroll approximately 3,000 subjects, with approximately 1,000 subjects in each cohort.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Give signed written informed consent to participate.

2. At least 40 years of age at baseline visit.

3. Previous or newly diagnosed by at least one of the 3 types of CVD which are,

   • Coronary heart disease ( CHD )
   • Atrial fibrillation (AF )
   • Chronic heart failure ( CHF )

4. Subjects have no absolute contraindications to spirometry testing.

5. Subjects have the cognitive ability to conduct questionnaires after e valuated by investigators.

Exclusion criteria

1. Significant diseases or conditions, which, in the opinion of the investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.
2. Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.
3. Subjects who are not able to provide written informed consent.
4. Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3,000 participants in 1 patient group

Guideline education and implementation

Other group

Treatment:

Behavioral: Guideline education and implementation intervention